WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 526985
Description: ZD-9379 is a NMDA receptor antagonist potentially for the treatment of pain and stroke. ZD9379 is also a glycine site antagonist, ZD9379 which reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion.
MedKoo Cat#: 526985
Chemical Formula: C19H14ClN3O4
Exact Mass: 383.0673
Molecular Weight: 383.788
Elemental Analysis: C, 59.46; H, 3.68; Cl, 9.24; N, 10.95; O, 16.67
Synonym: ZD-9379; ZD 9379; ZD9379.
IUPAC/Chemical Name: 7-Chloro-2,3-dihydro-2-(4-methoxy-2-methylphenyl)pyridazino [4,5-b] quinoline-1,4,10(5H)trione
InChi Key: PSTDMIAVUUYOOQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H14ClN3O4/c1-9-7-11(27-2)4-6-14(9)23-19(26)15-16(18(25)22-23)21-13-8-10(20)3-5-12(13)17(15)24/h3-8H,1-2H3,(H,21,24)(H,22,25)
SMILES Code: O=C1N(C2=CC=C(OC)C=C2C)NC(C(NC3=C4C=CC(Cl)=C3)=C1C4=O)=O
Appearance: White to off-white crystalline powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 383.788 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26. PubMed PMID: 12829411.
2: Tatlisumak T, Takano K, Meiler MR, Fisher M. A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Acta Neurochir Suppl. 2000;76:331-3. PubMed PMID: 11450037.
3: ZD 9379. Drugs R D. 1999 Jan;1(1):44-5. PubMed PMID: 10565985.
4: Tatlisumak T, Takano K, Meiler MR, Fisher M. A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Stroke. 1998 Jan;29(1):190-5. PubMed PMID: 9445350.
5: Qiu H, Hedlund LW, Gewalt SL, Benveniste H, Bare TM, Johnson GA. Progression of a focal ischemic lesion in rat brain during treatment with a novel glycine/NMDA antagonist: an in vivo three-dimensional diffusion-weighted MR microscopy study. J Magn Reson Imaging. 1997 Jul-Aug;7(4):739-44. PubMed PMID: 9243396.
6: Takano K, Tatlisumak T, Formato JE, Carano RA, Bergmann AG, Pullan LM, Bare TM, Sotak CH, Fisher M. Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke. 1997 Jun;28(6):1255-62; discussion 1263. PubMed PMID: 9183359.
170142-20-8 (ZD-9379 Free)
170142-29-7 (ZD-9379 sodium)